Abbott Prevails In $219M Whistleblower FCA Trial

Law360, Dallas (April 7, 2016, 5:58 PM EDT) -- A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219 million in damages.

In a 10-1 verdict returned after about three hours of deliberations, the jury found the medical device manufacturer had not violated the FCA by making false statements or submitting false records to the Centers for Medicare & Medicaid Services, bringing closure to the decade-old litigation.

During closing arguments in the three-week trial,...
To view the full article, register now.